333 例阿尔及利亚东部成人胶质瘤患者的流行病学和生存分析（2008-2016 年）。
Epidemiology and survival analyses of 333 adult glioma patients from Eastern Algeria (2008-2016).
机构信息
Laboratory of molecular and cellular biology, Mentouri Brothers University, Constantine, Algeria.
Radiation-Oncology Department, University Hospital Benbadis, Constantine, Algeria.
出版信息
Afr Health Sci. 2020 Sep;20(3):1250-1258. doi: 10.4314/ahs.v20i3.29.
BACKGROUND
Gliomas are a relatively rare group of tumors with a poor prognosis. We aimed to describe and analyze the clinical characteristics and survival of patients with glioma tumors of Eastern Algeria.
METHODS
A retrospective study was conducted at the University Hospital of Constantine. Medical records of patients enrolled between January 2008 and October 2016 were consulted. Demographic characteristics, clinical data, treatment strategy and dates of last follow-up or death were collected. Chi-square test was used for checking associations, Kaplan-Meier methodology for estimating the survival, and the cox model for identifying prognosis factors.
RESULTS
A total of 333 patients composed our cohort. The mean age was 48.07 years, and men were 1.87 times more frequent than women. High grade tumors were mainly observed among adults and old adults and in supra-tentorial locations. More than half of the patients had a large resection and a curative protocol of oncological treatment (50.7% and 57%, respectively). The mean overall survival was 45.4 months, the median was 21.7 months, and survival rates at 1-, 2-, and 5-years were: 62.8%, 48.5% and 32.9% respectively. Age, histology, grade of malignancy and oncological treatment were the major prognosis factors.
CONCLUSION
Our sample was relatively young with a higher survival compared to others.
背景
神经胶质瘤是一组预后较差的相对罕见肿瘤。本研究旨在描述和分析阿尔及利亚东部神经胶质瘤患者的临床特征和生存情况。
方法
这是一项在君士坦丁大学医院进行的回顾性研究。检索了 2008 年 1 月至 2016 年 10 月期间入组的患者的病历。收集了人口统计学特征、临床数据、治疗策略以及末次随访或死亡日期等信息。采用卡方检验评估相关性，Kaplan-Meier 法估计生存情况，Cox 模型识别预后因素。
结果
共纳入 333 例患者。平均年龄为 48.07 岁，男性是女性的 1.87 倍。高级别肿瘤主要发生在成年人和老年人中，且位于幕上部位。超过一半的患者接受了大切除和肿瘤治疗方案（分别为 50.7%和 57%）。总体中位生存时间为 21.7 个月，平均总生存时间为 45.4 个月，1 年、2 年和 5 年的生存率分别为 62.8%、48.5%和 32.9%。年龄、组织学、恶性程度分级和肿瘤治疗是主要的预后因素。
结论
本研究样本相对年轻，与其他研究相比生存情况较好。
Zotero 插件